纤溶酶原激活物抑制剂-1阻断在黑色素瘤免疫治疗中的潜在作用。
A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
作者信息
Del Rosso Mario, Fibbi Gabriella, Laurenzana Anna, Margheri Francesca, Chillà Anastasia
机构信息
Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
Department of Experimental and Clinical Biomedical Sciences, School of Human Health Sciences, University of Florence, Florence, Italy.
出版信息
J Invest Dermatol. 2021 Nov;141(11):2566-2568. doi: 10.1016/j.jid.2021.05.004.
In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained.
曾等人（2021年）在《皮肤病学研究杂志》上发表的新文章中证实，黑色素瘤细胞对抗PD-L1检查点抑制剂疗法的敏感性与高PD-L1表面表达相关。通过阻断由LRP1和PAI-1控制的PD-L1膜清除，维持了高细胞表面水平的PD-L1表达。
Zotero 插件